GLPG

Galapagos NV

29.50

USD

GLPG Earnings Reports

Positive Surprise Ratio

GLPG beat 25 of 38 last estimates.

66%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Galapagos NV earnings per share and revenue

On Feb 24, 2026, GLPG reported earnings of 11.87 USD per share (EPS) for Q4 25, beating the estimate of 2.76 USD, resulting in a 329.90% surprise. Revenue reached 900.77 million, compared to an expected 83.57 million, with a 977.93% difference. The market reacted with a -0.99% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Palvella Therapeutics, Inc. Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.92

Actual

-$1.08

Surprise

-16.19%

Bicara Therapeutics Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.68

Actual

-$0.68

Surprise

+0.66%

DiaMedica Therapeutics Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.17

Surprise

+7.41%

Neumora Therapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.33

Actual

-$0.35

Surprise

-5.39%

Sangamo Therapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-14.38%

RenovoRx, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.08

Surprise

+1.96%

INmune Bio Inc. Common stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.26

Actual

-$0.18

Surprise

+32.13%

PDS Biotechnology Corporation Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.14

Surprise

+27.76%

VolitionRX Limited Common Stock

Report Date

Mar 31, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.05

Surprise

-17.65%

Lantern Pharma Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.36

Surprise

+23.27%

FAQ

What were Galapagos NV's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Galapagos NV reported EPS of $11.87, beating estimates by 329.9%, and revenue of $900.77M, 977.93% above expectations.

How did the market react to Galapagos NV's Q4 2025 earnings?

The stock price moved down -0.99%, changed from $34.36 before the earnings release to $34.02 the day after.

When is Galapagos NV expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Galapagos NV's next earnings report?

Based on -- analysts, Galapagos NV is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.